Getty Images
Check Up: Oneview leads healthcare sector after ‘investor awareness’ pact
Health & Biotech
share
Here’s our fortnightly wrap of all the news driving ASX health stocks.
It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat.
| Code | Company | Price | % return since March 3 | %YTD return | % return since 17/3/20 | MktCap |
|---|---|---|---|---|---|---|
| SHG | Singular Health | 69.5 | 10.3 | $32,515,575 | ||
| RAC | Race Oncology | 391 | 0.0 | 123.4 | 1375.5 | $555,007,430 |
| AMT | Allegra Orthopaedics | 30 | -17.8 | -14.3 | 130.8 | $31,337,761 |
| RSH | Respiri | 16 | 10.3 | 23.1 | 116.2 | $111,962,822 |
| NC6 | Nanollose | 12.5 | 25.0 | 131.5 | 245.4 | $13,702,146 |
| CAJ | Capitol Health | 32 | -5.8 | 18.2 | 46.7 | $328,783,204 |
| CGS | Cogstate | 95.5 | -5.9 | -13.2 | 176.8 | $158,321,648 |
| NSB | Neuroscientific | 24 | 2.1 | -4.0 | 65.5 | $26,840,277 |
| PYC | PYC Therapeutics | 15 | 3.4 | 1.7 | 196.3 | $459,784,285 |
| ACW | Actinogen Medical | 3.4 | 47.8 | 61.9 | 116.8 | $51,477,315 |
| RNO | Rhinomed | 12 | -11.1 | -25.0 | 20.0 | $31,726,142 |
| JHC | Japara Healthcare Lt | 74.5 | -11.3 | 20.2 | 61.1 | $203,107,969 |
| RHY | Rhythm Biosciences | 144 | -5.6 | 64.6 | 2737.4 | $302,356,217 |
| BWX | BWX | 480 | 11.9 | 17.0 | 74.0 | $675,447,189 |
| SVA | Simavita | 1.7 | 0.0 | 6.3 | -5.6 | $23,671,965 |
| ALC | Alcidion Group | 29 | 11.5 | 56.8 | 114.8 | $292,254,745 |
| MX1 | Micro-X | 34.5 | -15.9 | -2.8 | 142.5 | $170,089,644 |
| TD1 | Tali Digital | 4.8 | -2.0 | 2.1 | 152.6 | $43,701,717 |
| RGS | Regeneus | 11.5 | -8.0 | -8.0 | 64.3 | $36,034,126 |
| ICR | Intelicare Holdings | 28 | 3.7 | 16.7 | $10,640,545 | |
| CDY | Cellmid | 8 | -6.6 | -21.9 | -14.0 | $9,795,347 |
| TRU | Truscreen | 9 | -6.3 | $32,657,963 | ||
| EYE | Nova EYE Medical | 33.5 | 0.0 | -5.6 | 11.8 | $48,134,856 |
| PNV | Polynovo | 272 | 11.0 | -29.9 | 80.1 | $1,818,817,121 |
| ICS | ICSGlobal | 204 | 1.5 | -3.3 | 22.6 | $21,468,999 |
| 4DX | 4Dmedical | 154 | -11.0 | -36.6 | $313,076,628 | |
| TLX | Telix Pharmaceutical | 421 | 5.3 | 11.4 | 325.3 | $1,166,379,586 |
| EZZ | EZZ Life Science | 80 | -31.0 | $8,940,000 | ||
| ALT | Analytica | 0.3 | 0.0 | 0.0 | 50.0 | $8,799,031 |
| SDI | SDI | 81 | 1.9 | 3.2 | 8.3 | $96,281,079 |
| OVN | Oventus Medical | 20 | -4.8 | -14.9 | -40.3 | $31,652,483 |
| JHL | Jayex Healthcare | 5 | 8.7 | 28.2 | 284.6 | $10,873,603 |
| RAP | Resapp Health | 7.3 | 23.7 | -14.1 | -12.0 | $59,620,820 |
| APH | AP Hemp | 45.5 | -1.1 | 33.8 | 468.8 | $35,819,814 |
| FFC | Farmaforce | 9.9 | 0.0 | 10.0 | 65.0 | $12,937,417 |
| ADR | Adherium | 2.1 | 16.7 | -25.0 | 16.7 | $14,271,516 |
| AHK | Ark Mines | 3.4 | 0.0 | 0.0 | 0.0 | $1,778,920 |
| EPN | Epsilon Healthcare | 23 | -6.1 | -2.1 | 4.5 | $42,852,814 |
| CYP | Cynata Therapeutics | 66.5 | 2.3 | -2.9 | -12.2 | $93,129,786 |
| CHM | Chimeric Therapeutic | 32.5 | 4.8 | $59,932,500 | ||
| 1ST | 1St Group | 3.4 | 6.3 | 0.0 | 13.3 | $15,286,209 |
| ONT | 1300 Smiles | 742 | 2.0 | 12.4 | 39.9 | $168,826,878 |
| LBT | LBT Innovations | 9.5 | -4.0 | -22.4 | -13.6 | $28,333,286 |
| UBI | Universal Biosensors | 53 | 24.7 | 21.8 | 253.3 | $88,767,184 |
| GSS | Genetic Signatures | 164 | 0.0 | -18.4 | 64.0 | $235,743,331 |
| MDR | Medadvisor | 33.5 | -9.5 | -5.6 | -19.1 | $120,424,851 |
| M7T | Mach7 Tech | 122.5 | -13.4 | -2.0 | 142.3 | $274,955,129 |
| HCT | Holista CollTech | 6.4 | -9.9 | -11.1 | -27.3 | $18,173,040 |
| NEU | Neuren Pharmaceut. | 130.5 | -0.4 | 1.6 | 8.8 | $151,282,703 |
| PBP | Probiotec | 228 | 3.6 | -4.2 | 18.6 | $178,111,932 |
| PAR | Paradigm Bio. | 251 | 2.0 | -1.6 | 75.5 | $569,153,461 |
| ARX | Aroa Biosurgery | 120 | -0.8 | 4.3 | $351,849,904 | |
| AGH | Althea Group | 54.5 | 5.8 | 25.3 | 194.6 | $141,681,712 |
| 1AD | Adalta | 18.5 | 8.8 | 48.0 | 201.2 | $44,131,654 |
| MVF | Monash IVF Group | 72.5 | -1.2 | -5.0 | 21.0 | $282,485,259 |
| MEM | Memphasys | 8.1 | -22.9 | -19.0 | 113.2 | $54,703,719 |
| SOM | SomnoMed | 190 | 7.2 | -9.5 | 10.7 | $153,104,733 |
| OSX | Osteopore | 45 | 0.0 | -13.5 | 28.6 | $35,117,010 |
| S66 | Star Combo | 29 | 0.0 | -12.1 | -38.3 | $39,066,616 |
| HXL | Hexima | 16.5 | 17.9 | -10.8 | -45.9 | $19,861,447 |
| PGC | Paragon Care | 23 | -14.8 | 2.2 | 53.3 | $74,334,764 |
| RCE | Recce Pharmaceutical | 102.5 | -1.0 | -2.8 | 259.6 | $175,515,625 |
| OPT | Opthea | 160.5 | -0.6 | -16.4 | -14.6 | $567,093,363 |
| OIL | Optiscan Imaging | 23 | 2.2 | 119.0 | 1433.3 | $140,805,021 |
| CYC | Cyclopharm | 255 | 0.8 | 2.0 | 220.0 | $234,370,806 |
| OSL | Oncosil Medical | 9.2 | -12.4 | -23.3 | 2.0 | $75,890,270 |
| IMU | Imugene | 12 | 20.0 | 20.0 | 566.7 | $547,353,921 |
| MEB | Medibio | 0.9 | 0.0 | 12.5 | 85.3 | $12,559,078 |
| NOX | Noxopharm | 68.5 | -1.4 | 39.8 | 356.3 | $191,027,559 |
| PIQ | Proteomics Int Lab | 131.5 | 5.2 | 65.4 | 526.2 | $139,724,314 |
| AT1 | Atomo Diagnostics | 27 | 10.2 | -11.5 | $112,169,843 | |
| MVP | Medical Developments | 550 | 0.0 | -17.7 | 11.3 | $399,794,810 |
| VTI | Vision Tech, | 1.8 | -5.3 | -28.0 | -35.7 | $16,893,335 |
| IVX | Invion | 0.9 | 0.0 | -10.0 | 28.6 | $49,840,131 |
| VLS | Vita Life Sciences.. | 119 | 30.8 | 19.0 | 88.8 | $59,490,873 |
| OSP | Osprey Med | 2.1 | 16.7 | -4.5 | 75.0 | $53,881,386 |
| CAN | Cann Group | 58.5 | -5.6 | -0.8 | -14.0 | $165,317,451 |
| VBS | Vectus Biosystems | 125 | 0.0 | 4.2 | 113.7 | $39,569,243 |
| ACR | Acrux | 15.5 | -8.8 | -6.1 | 40.9 | $45,189,577 |
| BPH | BPH Energy | 11.5 | -30.3 | 167.4 | 1226.0 | $79,790,327 |
| MDC | Medlab Clinical | 29.5 | -7.8 | 22.9 | 40.5 | $82,504,323 |
| DVL | Dorsavi | 4.1 | 28.1 | 0.0 | 152.3 | $12,282,640 |
| DOC | Doctor Care Anywhere | 101.5 | -16.8 | -15.4 | $181,724,249 | |
| OCC | Orthocell | 52 | 1.0 | 15.6 | 103.9 | $98,172,244 |
| PAA | Pharmaust | 10 | 2.0 | -4.8 | 42.9 | $31,039,532 |
| PXS | Pharmaxis | 8.7 | 6.1 | -6.5 | 29.9 | $33,367,639 |
| BIT | Biotron | 6.8 | -1.4 | -12.8 | -29.9 | $49,837,223 |
| PAB | Patrys | 2.4 | -7.7 | 0.0 | 72.6 | $45,300,420 |
| AHC | Austco Healthcare | 9.5 | 5.6 | -4.0 | 35.7 | $26,713,761 |
| NYR | Nyrada | 31.5 | 0.0 | 31.3 | 152.0 | $24,481,728 |
| KZA | Kazia Therapeutics | 134.5 | 1.9 | 15.9 | 157.5 | $170,220,193 |
| LSH | Lifespot Health | 12 | -4.0 | 55.8 | 312.1 | $20,216,035 |
| CMP | Compumedics | 40.5 | -3.6 | -19.0 | 1.3 | $76,180,068 |
| BXN | Bioxyne | 1.3 | 8.3 | 8.3 | 30.0 | $8,962,036 |
| PSQ | Pacific Smiles Grp | 260 | -3.7 | 2.0 | 143.0 | $407,769,039 |
| AVE | Avecho Biotech | 2.2 | 4.8 | -24.1 | 633.3 | $42,064,578 |
| ANP | Antisense Therapeut. | 18 | 12.5 | 38.5 | 339.0 | $106,200,349 |
| GTG | Genetic Technologies | 0.9 | -25.0 | 20.0 | 125.0 | $81,150,541 |
| NXS | Next Science | 127 | 2.4 | 1.6 | -20.1 | $145,624,322 |
| ONE | Oneview Healthcare | 22 | 182.1 | 388.9 | 417.1 | $77,568,640 |
| DXB | Dimerix | 26.5 | 12.8 | 12.8 | 96.3 | $50,489,821 |
| IDT | IDT Australia | 18.5 | -2.6 | 0.0 | 85.0 | $46,846,734 |
| SCU | Stemcell United | 2.7 | -3.6 | 42.1 | 170.0 | $22,688,658 |
| SUD | Suda Pharmaceuticals | 4.3 | -4.4 | 7.5 | 10.3 | $16,540,208 |
| ZNO | Zoono Group | 69.5 | 0.0 | -47.1 | -52.9 | $115,787,583 |
| BD1 | Bard1 Life Sciences | 390 | 33.6 | 473.5 | 490.9 | $328,098,293 |
| BOT | Botanix Pharma | 11.5 | 0.0 | -8.0 | 43.8 | $111,911,339 |
| IMC | Immuron | 21.5 | 2.4 | -6.5 | 156.0 | $48,858,018 |
| IBX | Imagion Biosys | 16 | -5.9 | 10.3 | 907.6 | $175,562,066 |
| LCT | Living Cell Tech. | 1.6 | -5.9 | 14.3 | 23.1 | $8,571,615 |
| CDX | Cardiex | 6.9 | -9.2 | 23.2 | 283.3 | $65,630,068 |
| CP1 | Cannpal Animal | 17 | 3.0 | 0.0 | 61.9 | $15,831,250 |
| CTE | Cryosite | 25.5 | 27.5 | -35.4 | 254.2 | $11,480,593 |
| MMJ | MMJ Group Hlds | 11.5 | -4.2 | -8.0 | 51.3 | $27,594,478 |
| PCK | PainChek | 7.6 | -6.2 | -1.3 | 2.7 | $77,749,531 |
| ZLD | Zelira Therapeutics | 6.8 | 1.5 | -26.1 | 119.4 | $78,561,316 |
| CPH | Creso Pharma | 19 | -7.3 | 5.6 | 216.7 | $181,169,749 |
| CBL | Control Bionics | 61 | -6.2 | -35.1 | $30,572,395 | |
| ATH | Alterity Therap | 3.4 | 0.0 | 9.7 | 161.5 | $70,856,567 |
| ATX | Amplia Therapeutics | 26 | 8.3 | 8.3 | 462.2 | $27,503,974 |
| EXL | Elixinol Global | 20 | 2.6 | 14.3 | -7.3 | $66,083,515 |
| IMM | Immutep | 37 | 10.4 | -10.8 | 17.5 | $240,028,356 |
| AC8 | Auscann Grp Hlgs | 15 | -3.2 | -23.1 | -9.1 | $49,142,340 |
| NTI | Neurotech Intl | 6.6 | -5.7 | 46.7 | 1220.0 | $37,756,894 |
| VHT | Volpara Health Tech | 129.5 | -0.4 | -9.8 | 12.6 | $328,834,996 |
| IPD | Impedimed | 10.5 | -4.5 | -16.0 | 64.9 | $131,800,728 |
| PAL | Palla Pharma | 51 | -12.8 | -33.8 | -22.3 | $75,173,989 |
| PTX | Prescient | 10 | 9.9 | 49.3 | 270.4 | $64,055,301 |
| IHL | Incannex Healthcare | 21 | 5.0 | 35.5 | 467.6 | $227,197,072 |
| BNO | Bionomics | 24 | -20.1 | 79.1 | 625.2 | $232,522,037 |
| RHT | Resonance Health | 18 | -5.3 | -25.0 | 80.0 | $80,649,097 |
| GLH | Global Health | 43 | 19.4 | -8.5 | 218.5 | $18,102,278 |
| MXC | Mgc Pharmaceuticals | 7.2 | -10.0 | 188.0 | 323.5 | $163,223,298 |
| ADO | Anteotech | 20.5 | 7.9 | 95.2 | 1181.3 | $374,748,269 |
Oneview Health (ASX:ONE) has been by far the biggest gainer, soaring 182 per cent in the period from March 3 to March 17 after entering into an investor awareness agreement with StocksDigital, the publisher of nextinvestors.com, wise-owl.com and catalysthunter.com.
Oneview says it will pay 6.25 million in shares in lieu of a $375,000 payment to StocksDigital for research and coverage over the next 18 months, and has agreed to sell StocksDigital another $1 million in shares at 6c – what was then an 18.9 per cent discount.
Next Investors recommended Oneview on March 12 as its “Technology Pick of the Year for 2021”, emailing subscribers that this was “the most undervalued company we have seen in ages”.
Oneview shares haven taken off since then, rising 175 per cent from 8c to 22c, taking its market capitalisation from $32 million to $88 million.
The company is working on the upcoming global launch of its cloud-based tablet solution for hospitals to manage patients at their bedside.
Actinogen Medical (ASX:ACW) was the second-biggest gainer, advancing 47.8 per cent to 3.4c. An announcement on Monday that Actinogen had appointed Dr Steven Gourlay as chief executive has seemed to boost sentiment. He’s been consulting for the company since December.
Actinogen is working to develop its lead drug compound, Xanamen, as a therapy for Alzheimer’s disease, Fragile X syndrome, schizophrenia and diabetes. It works by blocking the production of intracellular cortisol, the “stress hormone”.
Bard1 Life Sciences (ASX:BD1) rounds out the top three with a 33.6 per cent gain on a string of positive news including an Australian patent and promising early work on its exosome research to detect pancreatic cancer.
On the flip side, beauty and wellness company EZZ Life Science (ASX:EZZ) has fallen 31 per cent in the two weeks since March 3 – the day it listed.
EZZ shares have traded as high as $1.425 over the period but closed Wednesday at 80c – still up from its 50c IPO price.
Oneview, Actinogen, Bard1 and EZZ share chart
